Physician profile
Faisal Musa
NPI 1811138787
$975,683.95
in general payments reported to CMS, 2019-2025
63 companies · $86K in 2025
The $86K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126K · 2020: $17K · 2021: $157K · 2022: $158K · 2023: $202K · 2024: $229K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $374K · Travel and Lodging: $79K · Consulting Fee: $42K · Food and Beverage: $14K · Honoraria: $8,060 · Long Term Medical Supply Or Device Loan: $266 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $373,902.78 |
| Travel and Lodging | $78,996.52 |
| Consulting Fee | $41,989.00 |
| Food and Beverage | $13,649.91 |
| Honoraria | $8,060.00 |
| Long Term Medical Supply Or Device Loan | $266.36 |
| Education | $234.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $315,046.07 | 2021-2025 | Libtayo |
| Daiichi Sankyo INC. | $313,363.88 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals Lp | $73,595.52 | 2019-2025 | Enhertu, Datroway, Imfinzi |
| Merck Sharp & Dohme LLC | $56,469.85 | 2023-2024 | Keytruda, Lynparza |
| Genzyme Corporation | $47,956.57 | 2020-2025 | |
| Amgen INC. | $34,337.65 | 2021-2023 | Lumakras, Nplate, Xgeva |
| Amag Pharmaceuticals, INC. | $32,930.23 | 2021-2022 | |
| Astellas Pharma US INC | $29,578.26 | 2022-2024 | Xtandi, Padcev, Xospata |
| Pharmacosmos Therapeutics INC. | $15,418.63 | 2020-2023 | Monoferric |
| Sobi, INC | $15,238.05 | 2022-2025 | |
| Emd Serono, INC. | $11,063.32 | 2024 | |
| Shield Therapeutics INC | $4,877.72 | 2023 | Accrufer |
| Deciphera Pharmaceuticals INC. | $3,388.20 | 2024 | Qinlock |
| Janssen Biotech, INC. | $2,893.68 | 2022-2025 | Rybrevant, Erleada, Talvey |
| Geron Corporation | $2,840.92 | 2025 | Imetelstat |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,729.95 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Karyopharm Therapeutics INC. | $2,445.00 | 2022 | |
| Glaxosmithkline, LLC. | $2,334.32 | 2024-2025 | Ojjaara, Blenrep |
| Takeda Pharmaceuticals U.S.A., INC. | $1,962.76 | 2022-2025 | Fruzaqla |
| Morphosys, US INC. | $1,466.92 | 2021-2022 | |
| Seagen INC. | $1,364.52 | 2021-2023 | Padcev, Tukysa |
| Novartis Pharmaceuticals Corporation | $1,200.05 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.93 | 2024-2025 | Caplyta |
| Pfizer INC. | $253.71 | 2019-2025 | |
| Genentech USA, INC. | $246.16 | 2021-2025 | Polivy, Lunsumio, Tecentriq |
| Axsome Therapeutics, INC. | $228.89 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $180.75 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $135.95 | 2023-2025 | Cobenfy, Opdualag |
| Celgene Corporation | $133.71 | 2022-2025 | Reblozyl, Opdualag |
| Otsuka America Pharmaceutical, INC. | $126.84 | 2025 | Rexulti |
| Foundation Medicine, INC. | $114.74 | 2022-2023 | Foundationone Cdx |
| Exelixis INC. | $108.31 | 2023-2025 | Cabometyx |
| Array Biopharma INC | $93.30 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $90.95 | 2021-2025 | Fotivda |
| Eisai INC. | $90.31 | 2022-2024 | |
| Gilead Sciences, INC. | $89.65 | 2021-2025 | Trodelvy |
| Beigene USA, INC. | $86.46 | 2023-2024 | Brukinsa |
| Recordati_rare_diseases_inc. | $82.37 | 2023-2024 | Sylvant, Panhematin |
| Sirtex Medical INC | $78.73 | 2022 | |
| Asd Specialty Healthcare, LLC | $71.72 | 2024 | |
| Pharmaessentia USA Corporation | $69.10 | 2022-2025 | Besremi |
| Genmab U.S., INC. | $67.12 | 2024-2025 | Epkinly |
| Acrotech Biopharma INC. | $48.28 | 2023-2024 | Beleodaq |
| Kite Pharma, INC. | $43.17 | 2022-2023 | Yescarta |
| Blueprint Medicines Corporation | $42.22 | 2023-2024 | Ayvakit |
| Jazz Pharmaceuticals INC. | $40.28 | 2024 | |
| G1 Therapeutics, INC. | $38.06 | 2022-2023 | Cosela |
| Dendreon Pharmaceuticals LLC | $34.38 | 2025 | Provenge |
| Ipsen Biopharmaceuticals, INC | $34.18 | 2022-2024 | Onivyde, Somatuline Depot |
| Janssen Pharmaceuticals, INC | $33.43 | 2022-2024 | Xarelto |
| Abbvie INC. | $30.35 | 2022-2024 | |
| Syndax Pharmaceuticals, INC. | $27.49 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.39 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.43 | 2023 | Yonsa |
| Alexion Pharmaceuticals, INC. | $21.08 | 2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $19.49 | 2024 | |
| Agios Pharmaceuticals, INC. | $19.02 | 2024 | Pyrukynd |
| Tersera Therapeutics LLC | $18.18 | 2025 | Zoladex |
| Mayne Pharma Commercial LLC | $17.41 | 2022 | |
| Verity Pharmaceuticals INC. | $16.52 | 2023 | Sancuso |
| Cti Biopharma Corp. | $15.54 | 2023 | Vonjo |
| Lilly USA, LLC | $14.71 | 2021 | |
| Boston Scientific Corporation | $14.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Musa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.